Continuous glucose monitors (CGMs) aren’t just for people who use insulin pumps. In two studies involving a total of 319 people who took multiple daily injections, those who wore a CGM had lower A1C levels (a reflection of glucose control over time) after 24 to 26 weeks, compared with those who didn’t use a CGM. They also spent more time with in-range blood glucose and less time above and below target compared with those who did only four finger-stick blood glucose tests daily. Of course, CGM cost is still a problem for many people. Medicare’s recent decision to cover Dexcom’s G5 Mobile CGM should help some afford the devices.